You are here
Professor Martin Delatycki
Professor Martin Delatyki studied medicine at the University of Melbourne before completing his paediatric training at The Royal Children's Hospital. He went on to train in clinical genetics at the Victorian Clinical Genetics Services followed by a PhD studying the nervous system disease Friedreich ataxia at the Murdoch Childrens Research Institute. He is currently Co-Director of the Bruce Lefroy Centre and Director of Clinical Genetics at Austin Health.
2005: NHMRC 10 of the Best for the Haemscreen project
2010: Kyle Bryant Translational Research Award. Friedreich Ataxia Research Alliance: An open label pilot study of resveratrol as treatment for Friedreich ataxia
2012: Paul Harris Fellowship- Rotary Australia
2013: Bronya Keats International Research Collaboration Award, Friedreich Ataxia Research Alliance: Interstitial fibrosis, the renin-angiotensin-aldosterone system and biomarkers in the cardiac disease of Friedreich ataxia
Professor Delatyki's research interests are largely in neurogenetics and community genetics. He leads a team working on clinical research in Friedreich ataxia, a rare inherited nervous system disease. The team studies the effects of Friedreich ataxia on sufferers and undertakes clinical trials of pharmaceuticals and other interventions. One team is working on lentiviral gene therapy and bone marrow transplant for Friedreich ataxia.
Meanwhile, the group's work on Huntington disease includes studies on the impact of pre-morbid activity on the age of onset, a study on the needs of young people in Huntington disease families and studies on the impact of predictive testing for this condition.
Professor Delatyki is also leading a National Health and Medical Research Council (NHMRC)-funded study called Mi-Iron, which is examining the impact of treating moderate iron overload in hereditary haemochromatosis.
The team has a long-standing interest in community genetics and is undertaking studies of the impact of screening for genetic disease and ethical issues in genetics.
- Friedreich ataxia research
- Huntington disease research
- Mi-Iron- moderately increased iron- is reducing iron necessary?
- Genetic screening research
- Beta-propeller protein-associated neurodegeneration (BPAN)
Trembath K, Horton Z, Tippett L, Hogg V, Collins V, Churchyard A, Velakoulis D, Roxburgh R, Delatycki MB. A retrospective study of the impact of lifestyle on age at onset of Huntington disease. Mov Disord 25:1444-1450, 2010.
Evans-Galea MV, Carrodus N, Rowley SM,Corben LA, Tai G, Saffery R, Galati J, Wong NC, Craig JM, Lynch DR, Regner S, Brocht AFD, Perlman SL, Bushara KO, Gomez CM, Wilmot GR, Li L, Varley E, Delatycki MB, Sarsero JP. FXN methylation predicts expression and clinical outcome in Friedreich ataxia. Ann Neurol 71:487-497, 2012.
Delatycki MB, Wolthuizen M, Collins V, Varley E, Craven J, Allen KJ, Gurrin LC, Aitken MA, Trembath MK, Bond L, Wilson GR, Stephenson SEM, Macciocca I, Hickerton C, Lockhart PJ, Metcalfe SA. ironXS: High school screening for hereditary haemochromatosis is acceptable and feasible. Eur J Hum Genet 20:505-509, 2012.
Mand C, Gillam L, Duncan RE, Delatycki MB. “It was the missing piece" Adolescent experiences of predictive genetic testing for adult onset conditions. Genet Med 15:643-649, 2013.
Corben LA, Ho M, Copland J, Tai G, Delatycki MB. Increased prevalence of sleep disordered breathing in Friedreich ataxia. Neurology 81:46-51, 2013.